Daxor Corporation Common Stock
DXR US2394671034
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
Annual Performance 1
| 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -9% | -17% | 7% | -19% | 0% |
Annual Insiders Turnover, USD 2
1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);
Insider Activity
| Person | Price | Shares | Total | Published | Completed |
|---|---|---|---|---|---|
| Feldschuh Michael Richard CEO |
7.89 USD |
2,063 Bought |
16,277 USD |
04/04/2025 | 04/04/2025 |
| Feldschuh Michael Richard CEO |
7.68 USD |
3,360 Bought |
25,805 USD |
10/03/2025 | 10/03/2025 |
| Michel Robert J CFO |
8.00 USD |
1,000 Bought |
8,000 USD |
10/03/2025 | 10/03/2025 |
| Michel Robert J CFO |
8.70 USD |
750 Bought |
6,525 USD |
27/03/2024 | 27/03/2024 |
| Feldschuh Michael Richard SR OFF |
8.13 USD |
1,000 Bought |
8,130 USD |
26/03/2025 | 26/03/2024 |
| Feldschuh Michael Richard CEO |
8.15 USD |
647 Bought |
5,273 USD |
19/03/2025 | 19/03/2024 |
| Feuer Edward O |
7.21 USD |
1,000 Bought |
7,210 USD |
04/03/2024 | 04/03/2024 |
| Michel Robert J CFO |
7.75 USD |
120 Bought |
930 USD |
06/12/2023 | 06/12/2023 |
| Michel Robert J CFO |
7.75 USD |
180 Bought |
1,395 USD |
01/12/2023 | 01/12/2023 |
| Feldschuh Michael Richard CEO |
7.80 USD |
800 Bought |
6,240 USD |
01/12/2023 | 01/12/2023 |